|
**Overview**: **Rheumatoid Autoimmune Comprehensive Profile****Introduction**: The Rheumatoid Autoimmune Comprehensive Profile is a diagnostic tool designed to screen for rheumatoid autoimmune disorders using serum samples. Associated with conditions like rheumatoid arthritis and lupus, these disorders present with joint pain, swelling, and severe complications if untreated, particularly in individuals with suspected autoimmune conditions. Per the 2023 Immunology and Biochemistry guidelines, the test employs immunology and biochemistry with immunoassay and spectrophotometry technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for autoimmune screening in clinical settings. This diagnostic falls under autoimmune screening and targets individuals with suspected rheumatoid arthritis, addressing the challenge of accurate autoantibody assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Rheum Auto Pfl.**FDA Status**: FDA approved, CLIA certified for immunology and biochemistry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by rheumatology labs, this test advanced rheumatoid autoimmune screening.**Purpose**: The test screens for 10 parameters including rheumatoid factor to guide autoimmune assessment, assess autoantibody and inflammatory markers, and inform treatment and prevention strategies.**Test Parameters**: 1. Rheumatoid Factor, 2. Anti-CCP, 3. ANA, 4. Anti-dsDNA, 5. Anti-Ro, 6. Anti-La, 7. CRP, 8. ESR, 9. Uric Acid, 10. C3.**Pretest Condition**: No fasting required; patients should report joint pain, swelling, or recent autoimmune symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on joint pain, swelling, prior autoimmune reactions, or family history of autoimmune diseases, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune disorders including joint damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and spectrophotometry and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible rheumatoid autoimmune disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in rheumatology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Imaging or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Immunology and Biochemistry Guidelines 2023, Journal of Rheumatology 2024, Chemistry 2025. |
